This inventor holds 1 USPTO granted patent. Top assignee: Osaka Gas Company Limited. Active years: 1994.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1994
Title: Ryoichi Okura: Innovator in Monoclonal Antibody Development
Introduction
Ryoichi Okura is a distinguished inventor based in Nishinomiya, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His innovative work has implications for medical diagnostics and therapeutic applications.
Latest Patents
Ryoichi Okura holds a patent for a monoclonal antibody specifically recognizing the N-terminal portion of human calcitonin (hCT). This patent includes a hybridoma producing the monoclonal antibody, a process for preparing it, and a method for detecting hCT using this antibody. The monoclonal antibody allows for the detection of hCT with high sensitivity, which is crucial for various medical applications.
Career Highlights
Ryoichi Okura is associated with Osaka Gas Company Limited, where he has been able to apply his expertise in biotechnology. His work has not only advanced scientific knowledge but has also contributed to the practical applications of monoclonal antibodies in healthcare.
Collaborations
Some of his notable coworkers include Nobuhiko Yamashita and Manabu Nakamoto. Their collaborative efforts have further enhanced the research and development of innovative solutions in the field.
Conclusion
Ryoichi Okura's contributions to the development of monoclonal antibodies exemplify the impact of innovation in biotechnology. His work continues to influence the medical field, paving the way for advancements in diagnostics and treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile